Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EnVivo Pharmaceuticals Announces Appointment of President and Chief Executive Officer

Published: Friday, July 12, 2013
Last Updated: Friday, July 12, 2013
Bookmark and Share
Industry leader to direct company growth, commercialization of phase 3 programs in Alzheimer’s disease and schizophrenia, and expansion of diverse CNS pipeline.

EnVivo Pharmaceuticals announced the appointment of Deborah Dunsire, M.D., as president and chief executive officer. She also joins the company’s board of directors. Dr. Dunsire, formerly president and chief executive officer of Millennium: The Takeda Oncology Company, brings more than 25 years of scientific, clinical, operational and commercial experience, and proven leadership in the biological and pharmaceutical industry.

Dr. Dunsire served as president and chief executive officer of Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, from 2005 to 2013. During that period, she transformed the company into a biotechnology industry leader by focusing R&D, driving the development pipeline, fostering a culture of employee engagement and increasing the commercial mindset across the organization to enhance the commercial success of marketed products. The company was acquired by Takeda Pharmaceutical Company Limited in 2008 for $8.8 billion – one of the largest biotech acquisitions at that time – and became Millennium: The Takeda Oncology Company. Dr. Dunsire was the first woman appointed to Takeda’s board of directors.

“Deborah’s ability to build a fully integrated biopharmaceutical company with an award-winning culture of innovation and successfully commercialize late-stage programs while developing a leading research pipeline is unparalleled,” said Stephen Knight, M.D., chairman of the EnVivo board of directors and president of Fidelity Biosciences. “She joins EnVivo at a transformative point in the company’s evolution, as our lead product, EVP-6124, is in Phase 3 clinical trials in schizophrenia and will enter a Phase 3 clinical trial in Alzheimer’s disease later this year. We are excited to work with Deborah to build EnVivo toward global CNS leadership.

I thank Robert Weisskoff, Ph.D., for his exceptional leadership as interim chief executive officer as he resumes his prior role as a member of the company's board of directors.”

“CNS diseases, including Alzheimer’s disease and schizophrenia, take a devastating toll on patients, families and the health care system,” said Dr. Dunsire. “EnVivo’s late-stage lead product candidate and broad pipeline of promising clinical programs present a unique and compelling opportunity to develop new therapies with the potential to make a dramatic impact on patients’ lives. I am looking forward to working with the EnVivo team to purpose-build a biopharmaceutical company focused on transforming the CNS treatment landscape.”

Prior to leading Millennium, Dr. Dunsire led the Novartis U.S. Oncology Business, playing a critical role in the broad development and successful launch of a number of products. Over 10 years, she increased the North American oncology revenues from $50 million to more than $2.2 billion. She served on the U.S. Pharmaceutical Executive Committee at Novartis. Dr. Dunsire is currently a board member of Allergan, Inc., the Biotechnology Industry Organization (BIO), Museum of Science (Boston), Massachusetts General Hospital Research Advisory Council, CancerCare (New York) and the Gabrielle's Angels Foundation for Cancer Research. She has received numerous awards, including the 2001 American Cancer Society Excalibur Award, the 2009 Healthcare Businesswomen’s Association’s “Woman of the Year”, the 2011 MassBIO Innovator Award and the 2013 Boston CEO Conference Lifetime Achievement award. Dr. Dunsire received her medical degree from the University of Witwatersand, Johannesburg, South Africa.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Novel Technique for Kidney Research Developed
To better understand how the treatment leads to kidney damage, and possibly prevent it, a team of researchers at Yale School of Medicine developed a new 3D-imaging technique to peer deep into these vital organs.
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
A Better Way to Personalize Bladder Cancer Treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.
Breath of Fresh Air for Asthmatics
Researchers hope to develop a platform that will allow a range of drugs to be delivered by inhalation.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Elastic Patch Releases Drugs in a Stretch
Researchers from have developed a drug delivery technology that consists of an elastic patch that can be applied to the skin and will release drugs whenever the patch is stretched.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Liposomes: A Basis for Drugs of the Future
An international group of scientists have recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!